Nutromics

Executive Summary

Nutromics is pioneering continuous diagnostic monitoring with a novel platform that combines DNA-based sensors and microneedle patches worn on the arm. Founded in 2018, the company aims to eliminate preventable deaths caused by inadequate monitoring of key health biomarkers. Its technology promises to deliver real-time molecular insights, moving beyond traditional glucose monitors to track a broader range of analytes, such as drugs, hormones, or proteins, directly from interstitial fluid. This approach could revolutionize early detection and management of chronic diseases, potentially reducing hospitalization and improving patient outcomes. Nutromics' vision aligns with the growing demand for non-invasive, wearable diagnostics, positioning it at the forefront of the digital health and diagnostics sectors.

Upcoming Catalysts (preview)

• H2 2026First-in-human clinical trial results70% success
• Q1 2027FDA breakthrough device designation50% success
• Q4 2026Strategic partnership for manufacturing and distribution60% success